Amgen to Acquire Tavneos Maker ChemoCentryx for USD 52/Share.

MANews-(C)2009-2022

US-based biotechnology company Amgen (NASDAQ: AMGN) has entered into a definitive agreement under which it will acquire biopharmaceutical company ChemoCentryx, Inc., (NASDAQ: CCXI) for USD 52 per share in cash, representing an enterprise value of approximately USD 3.7bn, the company said.

ChemoCentryx is focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Tavneos is an orally administered selective complement component 5a receptor inhibitor.

It was approved by the US Food and Drug Administration in October 2021 as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis (the two main forms of ANCA-associated vasculitis), in combination with standard therapy.

ANCA-associated vasculitis is an umbrella term for a group of multi-system autoimmune diseases with small vessel inflammation. Inflamed vessels may rupture or become occluded giving rise to a range of clinical symptoms and signs related to a systemic inflammatory response which may result in profound injury and dysfunction in the kidneys, lungs and other organs.

Amgen is in inflammation and nephrology. The company's inflammation portfolio includes Otezla, Enbrel, Tezspire, Amgevita (a biosimilar to Humira), Riabni (a biosimilar to Rituxan), and Avsola (a biosimilar to Remicade).

Amgen's pipeline includes four innovative Phase 2 inflammation medicines efavaleukin alpha for systemic lupus erythematosus and ulcerative colitis, ordesekimab for celiac disease, rocatinlimab for atopic dermatitis and rozibafusap alfa for systemic lupus erythematosus as...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT